Logo-jnp
J Nephropathol. 2015;4(2): 48-53.
doi: 10.12860/jnp.2015.10
PMID: 25964889
PMCID: PMC4417670
Scopus ID: 84927143060
  Abstract View: 1976
  PDF Download: 1027

Original Article

Effect of pioglitazone therapy on high sensitive C-reactive protein and lipid profile in diabetic patients with renal transplantation; a randomize clinical trial

Rana Arashnia 1, Kobra Roohi-Gilani 1, Hamidreza Karimi-Sari 2 * , Niloofar Nikjoo 3, Ali Bahramifar 1

1 Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid-Beheshti University of Medical Sciences, Tehran, Iran
2 Students’ Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran
3 Students’ Research Committee, Iran University of Medical Sciences, Tehran, Iran
*Corresponding author: Hamidreza Karimi-Sari, Students’ Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran. dr.karimih@yahoo.com

Abstract

Background: Inflammation has a major role in disease lead to renal failure and diabetes mellitus, controlling inflammation in diabetic kidney receivers could decrease morbidity and mortality.

Objectives: This study designed for evaluating the efficacy of pioglitazone on C-reactive protein and lipid profile in diabetic kidney transplant receivers.

Patients and Methods: In this double blinded clinical trial, 58 diabetic renal transplant receivers, in first month after transplantation, randomized into two groups; receiving insulin and pioglitazone (15 mg tablet daily, group A); and insulin and placebo (group B). Blood pressure, weight, body mass index (BMI) and laboratory data compared in before and after 4-month treatment in two groups by SPSS.

Results: Fifty-eight patients with mean age of 44.15 ± 2 years included. There were no significant difference between groups in demographic data and other baseline measured variables (P > 0.05) .The mean weigh and BMI were slightly increased in group A and decreased in group B. The mean hs-CRP was decreased 4.82 mg/dL in group A and 1.93 mg/dL in group B (P = 0.007). The mean total serum cholesterol was significantly decreased 34 mg/dL in group A and 18.07 mg/dL in group B (P = 0.027). The mean serum HDL-C was significantly increased 13.31 mg/dL in group A and 5.89 mg/dl in group B (P < 0.001).

Conclusions: Pioglitazone seems to be a safe drug for reducing serum lipids and CRP in kidney transplant receivers with diabetes mellitus in short term. Long term effect of this drug could be evaluated in future studies.

Keywords: Pioglitazone, C-reactive protein, Cholesterol, Diabetes mellitus, Kidney transplantation

Implication for health policy/practice/research/medical education:

Pioglitazone could control inflammatory process in diabetic renal transplant receivers and decrease inflammatory related morbidities.

Please cite this paper as: Arashnia R, Roohi-Gilani K, Karimi-Sari HR, Nikjoo N, Bahramifar A. Effect of pioglitazone therapy on high sensitive C-reactive protein and lipid profile in diabetic patients with renal transplantation; a randomize clinical trial. J Nephropathol 2015; 4(2):48-53. DOI: 10.12860/jnp.2015.10

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 1976

Your browser does not support the canvas element.


PDF Download: 1027

Your browser does not support the canvas element.

ePublished: 01 Apr 2015
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)